Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.46 |
| ▸ | GABRD | O14764 | 2/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.46 |
| ▸ | GABRE | P78334 | 2/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.46 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.46 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.46 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alanine SCHEMBL146570 | 1.00 | GABRP (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| D-Alanine SCHEMBL11973777 | 1.00 | GABRP (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Alanine SCHEMBL15658201 | 0.88 | SLC7A5 (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Glycolic Acid SCHEMBL21145253 | 0.88 | — | — | |
| Alanine SCHEMBL28160913 | 0.87 | — | — | |
| Alanine SCHEMBL15123430 | 0.87 | — | — | |
| Alanine SCHEMBL9064738 | 0.85 | — | — | |
| Glycolic Acid SCHEMBL1832707 | 0.85 | — | — | |
| Alanine SCHEMBL9397402 | 0.85 | — | — | |
| D-Alanine SCHEMBL2027760 | 0.84 | SLC7A5 (0.59) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115667534-A | Lentiviral vectors | 牛津生物医学（英国）有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115667533-A | Production of lentiviral vectors | 牛津生物医学（英国）有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-114667161-A | Production system | 牛津生物医学（英国）有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-114174513-A | Optimized production of lentiviral vectors | 牛津生物医学（英国）有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2020-02-13 | — | — | US | disclosed |
| EP-3566719-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES | Cerulean Pharma Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| US-20180193486-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180117168-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | COLE RODERIC O (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180015170-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC (US) | 2018-01-18 | — | — | US | disclosed |
| US-20170368194-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC (US) | 2017-12-28 | — | — | US | disclosed |
| WO-2012044832-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | FETZER OLIVER S (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-03-08 | — | — | US | disclosed |
| EP-2413901-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | Cerulean Pharma Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2011146638-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES | CERULEAN PHARMA INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-09-29 | — | — | US | disclosed |
| WO-2011063421-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2010117668-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010114770-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114768-A1 | POLYMER-EPOTHILONE CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | GABRP 1632/4885GABRD 1347/4885GABRA1 2849/4885 |
| US-20170368194-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | GABRP 2068/4885GABRD 1450/4885GABRA1 2643/4885 |
| US-20180193486-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | GABRP 3913/4885GABRD 3941/4885GABRA1 4265/4885 |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | GABRP 1632/4885GABRD 1347/4885GABRA1 2849/4885 |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | GABRP 3913/4885GABRD 3941/4885GABRA1 4265/4885 |
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | GABRP 2068/4885GABRD 1450/4885GABRA1 2643/4885 |
| US-20180117168-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | JAK2, JAK3, JAK1 | GABRP 710/4885GABRD 829/4885GABRA1 1273/4885 |
| US-20180015170-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | GABRP 1632/4885GABRD 1347/4885GABRA1 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.